ClinicalTrials.Veeva

Find clinical trials for Melanoma in Phoenix, AZ

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Phoenix, AZ, USA:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Scottsdale, Arizona, United States and 21 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Phoenix, Arizona, United States and 70 other locations

Tumor Treating Fields targeted to liver metastases may improve outcomes for patients with metastatic uveal melanoma treated with immune chec...

Enrolling
Uveal Melanoma
Drug: Opdivo
Drug: Yervoy

Phase 1

HonorHealth Research Institute

Scottsdale, Arizona, United States and 1 other location

antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Scottsdale, Arizona, United States and 62 other locations

A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibit...

Active, not recruiting
Melanoma
Biological: Lerapolturev
Biological: Anti-PD-1 Checkpoint Inhibitor

Phase 2

Istari Oncology

Scottsdale, Arizona, United States and 11 other locations

UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma an...

Active, not recruiting
Malignant Melanoma
Biological: Ipilimumab
Biological: UV1

Phase 2

Ultimovacs

Phoenix, Arizona, United States and 36 other locations

The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...

Enrolling
Melanoma
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab+rHuPH20

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Phoenix, Arizona, United States and 34 other locations

administered to participants with unresectable or metastatic melanoma.The study is divided into two phases: Phase 2 and Phase 3.The primary ...

Active, not recruiting
Advanced Melanoma
Melanoma
Drug: Nivolumab
Drug: CMP-001

Phase 2, Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Phoenix, Arizona, United States and 19 other locations

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Phoenix, Arizona, United States and 189 other locations

manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant thera...

Enrolling
Melanoma Stage IIIB/C
Drug: Adjuvant therapy
Drug: Daromun

Phase 3

Philogen
Philogen

Phoenix, Arizona, United States and 33 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems